Literature DB >> 35501170

Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications.

Evrim B Turkbey1, Jye-Yu C Backlund2, Neville Gai3, Marcelo Nacif4, Rob J van der Geest5, John M Lachin2, Anderson Armstrong6, Gustavo J Volpe7, Saman Nazarian8, João A C Lima9, David A Bluemke10.   

Abstract

Alterations in myocardial structure, function, tissue composition (e.g., fibrosis) may be associated with metabolic syndrome (MetS). This study aimed to determine the relation of MetS and its individual components to markers of cardiovascular disease in patients with type 1 Diabetes Mellitus (T1DM). A total of 978 subjects of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications T1DM cohort (age: 49 ± 7 years, 47% female, DM duration 28 ± 5 years) underwent cardiovascular magnetic resonance. In a subset of 200 patients, myocardial tissue composition was measured with cardiovascular magnetic resonance T1 mapping after contrast administration. MetS was defined as T1DM plus 2 other abnormalities based on the American Heart Association/National Cholesterol Education Program criteria. MetS was present in 34.1% of subjects. After adjustment for age, height, scanner, study cohort, gender, smoking, mean glycated hemoglobin levels, history of macroalbuminuria and end-stage renal disease, left ventricle mass was greater by 12.3 g, end-diastolic volume was higher by 5.4 ml, and mass to end-diastolic volume ratio was higher by 5% in patients with MetS versus those without MetS (p <0.001 for all). Myocardial T1 times were lower by 29 ms in patients with MetS than those without (p <0.001). Elevated waist circumference showed the strongest associations with left ventricle mass (+10.1 g), end-diastolic volume (+6.7 ml), and lower myocardial T1 times (+31 ms) in patients with MetS compared with those without (p <0.01). In conclusion, in a large cohort of patients with T1DM, 34.1% of subjects met MetS criteria. MetS was associated with adverse myocardial structural remodeling and change in myocardial tissue composition.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35501170      PMCID: PMC9167770          DOI: 10.1016/j.amjcard.2022.03.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   3.133


  29 in total

1.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 2.  Myocardial lipid accumulation in the diabetic heart.

Authors:  Frederick L Ruberg
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

Review 3.  Metabolic syndrome: its history, mechanisms, and limitations.

Authors:  Eiji Oda
Journal:  Acta Diabetol       Date:  2011-07-01       Impact factor: 4.280

4.  The effect of features of the metabolic syndrome on atherosclerotic risk in relatively long-surviving patients with type 1 diabetes.

Authors:  Larry A Distiller; Barry I Joffe; Vanessa Brown; Greg B Distiller
Journal:  Metab Syndr Relat Disord       Date:  2010-09-06       Impact factor: 1.894

5.  The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience.

Authors:  Georgia Pambianco; Tina Costacou; Trevor J Orchard
Journal:  Diabetes Care       Date:  2007-02-15       Impact factor: 19.112

Review 6.  Diabetic cardiomyopathy: How can cardiac magnetic resonance help?

Authors:  Marijana Tadic; Cesare Cuspidi; Francesca Calicchio; Guido Grassi; Giuseppe Mancia
Journal:  Acta Diabetol       Date:  2020-04-13       Impact factor: 4.280

7.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

8.  The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation.

Authors:  R K Simmons; K G M M Alberti; E A M Gale; S Colagiuri; J Tuomilehto; Q Qiao; A Ramachandran; N Tajima; I Brajkovich Mirchov; A Ben-Nakhi; G Reaven; B Hama Sambo; S Mendis; G Roglic
Journal:  Diabetologia       Date:  2009-12-11       Impact factor: 10.122

9.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

10.  Blood pressure-independent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: a population-based study.

Authors:  J Sundström; J Arnlöv; K Stolare; L Lind
Journal:  Heart       Date:  2007-10-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.